These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

825 related items for PubMed ID: 10653879

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
    Xiong J, Liu Y, Li C, Zhu JJ, Ye ZR, Mao Y, Wang Y.
    Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
    [Abstract] [Full Text] [Related]

  • 26. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.
    Godfraind C, Rousseau E, Ruchoux MM, Scaravilli F, Vikkula M.
    Neuropathol Appl Neurobiol; 2003 Oct; 29(5):462-71. PubMed ID: 14507338
    [Abstract] [Full Text] [Related]

  • 27. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ.
    Cancer; 2005 Feb 15; 103(4):802-9. PubMed ID: 15637687
    [Abstract] [Full Text] [Related]

  • 28. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma.
    Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, von Deimling A.
    J Neuropathol Exp Neurol; 1995 Jan 15; 54(1):91-5. PubMed ID: 7815084
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
    Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP.
    Am J Pathol; 1994 Nov 15; 145(5):1175-90. PubMed ID: 7977648
    [Abstract] [Full Text] [Related]

  • 31. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
    Snuderl M, Eichler AF, Ligon KL, Vu QU, Silver M, Betensky RA, Ligon AH, Wen PY, Louis DN, Iafrate AJ.
    Clin Cancer Res; 2009 Oct 15; 15(20):6430-7. PubMed ID: 19808867
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.
    Li J, Miao N, Liu M, Cui W, Liu X, Li X, Shi X, Qing S, Ma Y, Zhang W, Biekemituofu H.
    Int J Clin Exp Pathol; 2014 Oct 15; 7(12):8609-15. PubMed ID: 25674225
    [Abstract] [Full Text] [Related]

  • 35. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
    Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC.
    Cancer Res; 2006 Oct 15; 66(20):9852-61. PubMed ID: 17047046
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
    Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S.
    Neuro Oncol; 2013 Jun 15; 15(6):775-82. PubMed ID: 23486687
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.